UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers

Breast cancer research : BCR, 2014-06, Vol.16 (3), p.211-211, Article 211

2014

Volltextzugriff (PDF)

The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatin

Nature cell biology, 2022-01, Vol.24 (1), p.62-73

2022

Volltextzugriff (PDF)

Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors

Annual review of medicine, 2015-01, Vol.66 (1), p.455-470

2015

Volltextzugriff (PDF)

BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of poly (ADP-ribose) polymerase: An issue of potency

Cancer biology & therapy, 2005-09, Vol.4 (9), p.934-936

2005

Volltextzugriff (PDF)

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Nature, 2005-04, Vol.434 (7035), p.917-921

2005

Volltextzugriff (PDF)

Genomic profiling and pre-clinical modelling of breast cancer leptomeningeal metastasis reveals acquisition of a lobular-like phenotype

Nature communications, 2023-11, Vol.14 (1), p.7408-7408, Article 7408

2023

Volltextzugriff (PDF)

Targeting folate receptor alpha for cancer treatment

Oncotarget, 2016-08, Vol.7 (32), p.52553-52574

2016

Volltextzugriff (PDF)

RORγt + Innate Lymphoid Cells Promote Lymph Node Metastasis of Breast Cancers

Cancer research (Chicago, Ill.), 2017-03, Vol.77 (5), p.1083-1096

2017

Volltextzugriff (PDF)

Mutation Processes in 293-Based Clones Overexpressing the DNA Cytosine Deaminase APOBEC3B

PloS one, 2016-05, Vol.11 (5), p.e0155391

2016

Volltextzugriff (PDF)

PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor—positive breast cancer

Proceedings of the National Academy of Sciences - PNAS, 2010-06, Vol.107 (22), p.10208-10213

2010

Volltextzugriff (PDF)

Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)

Oncoimmunology, 2018-03, Vol.7 (3), p.e1395127

2018

Volltextzugriff (PDF)

Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence?

Breast cancer research : BCR, 2012-11, Vol.14 (6), p.115-115, Article 115

2012

Volltextzugriff (PDF)

A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-∆11q splice variant

Oncogene, 2023-09, Vol.42 (36), p.2701-2709

2023

Volltextzugriff (PDF)

Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition

Cancer research (Chicago, Ill.), 2006-08, Vol.66 (16), p.8109-8115

2006

Volltextzugriff (PDF)

Biologic markers determine both the risk and the timing of recurrence in breast cancer

Breast cancer research and treatment, 2011-09, Vol.129 (2), p.607-616

2011

Volltextzugriff (PDF)

A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor

The EMBO journal, 2008-05, Vol.27 (9), p.1368-1377

2008

Volltextzugriff (PDF)

Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types

Frontiers in immunology, 2018-01, Vol.8, p.1911-1911

2018

Volltextzugriff (PDF)

Comparison of basal-like triple-negative breast cancer defined by morphology, immunohistochemistry and transcriptional profiles

Modern pathology, 2013-07, Vol.26 (7), p.955-966

2013

Volltextzugriff (PDF)

Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs)

Scientific reports, 2020-06, Vol.10 (1), p.8869, Article 8869

2020

Volltextzugriff (PDF)

Targeting TAO Kinases Using a New Inhibitor Compound Delays Mitosis and Induces Mitotic Cell Death in Centrosome Amplified Breast Cancer Cells

Molecular cancer therapeutics, 2017-11, Vol.16 (11), p.2410-2421

2017

Volltextzugriff (PDF)

Integrated genomics and functional validation identifies malignant cell specific dependencies in triple negative breast cancer

Nature communications, 2018-03, Vol.9 (1), p.1044-16, Article 1044

2018

Volltextzugriff (PDF)

Opinion: PARP inhibitors in cancer-what do we still need to know?

Open biology, 2022-07, Vol.12 (7), p.220118

2022

Volltextzugriff (PDF)

Engineering and stable production of recombinant IgE for cancer immunotherapy and AllergoOncology

Journal of allergy and clinical immunology, 2018-04, Vol.141 (4), p.1519-1523.e9

2018

Volltextzugriff (PDF)

PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer

The Journal of clinical investigation, 2019-03, Vol.129 (3), p.1211-1228

2019

Volltextzugriff (PDF)

Cancer‐associated FBXW7 loss is synthetic lethal with pharmacological targeting of CDC7

Molecular oncology, 2024-02, Vol.18 (2), p.369-385

2024

Volltextzugriff (PDF)

1 – 25 von 105

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(98)
Mit Volltextzugriff
(89)

Publikationsform

Sprache

Englisch
(105)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers

The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatin

Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors

BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of poly (ADP-ribose) polymerase: An issue of potency

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Genomic profiling and pre-clinical modelling of breast cancer leptomeningeal metastasis reveals acquisition of a lobular-like phenotype

Targeting folate receptor alpha for cancer treatment

RORγt + Innate Lymphoid Cells Promote Lymph Node Metastasis of Breast Cancers

Mutation Processes in 293-Based Clones Overexpressing the DNA Cytosine Deaminase APOBEC3B

PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor—positive breast cancer

Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)

Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence?

A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-∆11q splice variant

Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition

Biologic markers determine both the risk and the timing of recurrence in breast cancer

A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor

Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types

Comparison of basal-like triple-negative breast cancer defined by morphology, immunohistochemistry and transcriptional profiles

Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs)

Targeting TAO Kinases Using a New Inhibitor Compound Delays Mitosis and Induces Mitotic Cell Death in Centrosome Amplified Breast Cancer Cells

Integrated genomics and functional validation identifies malignant cell specific dependencies in triple negative breast cancer

Opinion: PARP inhibitors in cancer-what do we still need to know?

Engineering and stable production of recombinant IgE for cancer immunotherapy and AllergoOncology

PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer

Cancer‐associated FBXW7 loss is synthetic lethal with pharmacological targeting of CDC7

Suchergebnisse filtern